Following FDA approval in 2024, Lumicell’s LumiSystem for real-time cancer detection is now commercially available in the U.S. Developed with early support from the Koch Institute Frontier Research Program, it reveals residual cancer cells during surgery to enable precise and efficient correction, improve patient outcomes and reduce the need for additional treatments.